OMG

Summary

OMG (oligodendrocyte myelin glycoprotein, HGNC:8135) is a protein-coding gene on chromosome 17q11.2, encoding Oligodendrocyte-myelin glycoprotein (P23515). Cell adhesion molecule contributing to the interactive process required for myelination in the central nervous system.

Predicted to enable identical protein binding activity. Predicted to be involved in neuron projection regeneration. Predicted to act upstream of or within regulation of collateral sprouting of intact axon in response to injury. Predicted to be located in plasma membrane.

Source: NCBI Gene 4974 — RefSeq curated summary.

At a glance

• GWAS associations: 4
• Clinical variants (ClinVar): 4 total — 1 pathogenic
• MANE Select transcript: NM_002544

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:8135
Approved symbol	OMG
Name	oligodendrocyte myelin glycoprotein
Location	17q11.2
Locus type	gene with protein product
Status	Approved
Aliases	OMGP
Ensembl gene	ENSG00000126861
Ensembl biotype	protein_coding
OMIM	164345
Entrez	4974

Gene structure

Transcript identifiers

Ensembl transcripts: 4 — 2 protein_coding_CDS_not_defined, 1 protein_coding, 1 retained_intron

ENST00000247271, ENST00000580156, ENST00000582029, ENST00000584094

RefSeq mRNA: 1 — MANE Select: NM_002544 NM_002544

CCDS: CCDS11265

Canonical transcript exons

ENST00000247271 — 2 exons

Exon	Start	End
ENSE00001265045	31297156	31297239
ENSE00001308281	31294647	31296337

Expression profiles

Bgee: expression breadth ubiquitous, 215 present calls, max score 98.98.

FANTOM5 (CAGE): breadth broad, TPM avg 11.5029 / max 976.9348, expressed in 383 samples.

FANTOM5 promoters (8 alternative TSS)

Promoter ID	TPM avg	Samples expressed
165215	5.6822	108
165214	3.3672	98
165206	1.9223	272
165216	0.3424	83
165210	0.0638	19
165211	0.0591	10
165213	0.0432	7
165212	0.0228	9

Top tissues by expression

293 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
olfactory segment of nasal mucosa	UBERON:0005386	98.98	gold quality
bronchial epithelial cell	CL:0002328	98.80	gold quality
postcentral gyrus	UBERON:0002581	98.34	gold quality
lateral globus pallidus	UBERON:0002476	98.30	gold quality
pons	UBERON:0000988	98.24	gold quality
Brodmann (1909) area 46	UBERON:0006483	98.17	gold quality
corpus callosum	UBERON:0002336	98.09	gold quality
middle frontal gyrus	UBERON:0002702	98.01	gold quality
subthalamic nucleus	UBERON:0001906	97.92	gold quality
parietal lobe	UBERON:0001872	97.89	gold quality
orbitofrontal cortex	UBERON:0004167	97.88	gold quality
lateral nuclear group of thalamus	UBERON:0002736	97.82	gold quality
inferior vagus X ganglion	UBERON:0005363	97.68	gold quality
substantia nigra pars reticulata	UBERON:0001966	97.60	gold quality
entorhinal cortex	UBERON:0002728	97.59	gold quality
inferior olivary complex	UBERON:0002127	97.54	gold quality
dorsal plus ventral thalamus	UBERON:0001897	97.53	gold quality
middle temporal gyrus	UBERON:0002771	97.08	gold quality
prefrontal cortex	UBERON:0000451	97.06	gold quality
superior frontal gyrus	UBERON:0002661	97.02	gold quality
substantia nigra pars compacta	UBERON:0001965	97.01	gold quality
superior vestibular nucleus	UBERON:0007227	96.98	gold quality
Brodmann (1909) area 9	UBERON:0013540	96.86	gold quality
Ammon’s horn	UBERON:0001954	96.83	gold quality
medulla oblongata	UBERON:0001896	96.77	gold quality
temporal lobe	UBERON:0001871	96.65	gold quality
endothelial cell	CL:0000115	96.63	gold quality
Brodmann (1909) area 23	UBERON:0013554	96.63	gold quality
CA1 field of hippocampus	UBERON:0003881	96.62	gold quality
caudate nucleus	UBERON:0001873	96.43	gold quality

Single-cell (SCXA)

Detected in 6 experiment(s), a significant marker in 6.

Experiment	Marker?	Max mean expression
E-CURD-114	yes	63.68
E-HCAD-1	yes	26.90
E-MTAB-10287	yes	25.47
E-GEOD-84465	yes	22.17
E-GEOD-93593	yes	4.58
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

55 targeting OMG, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-30A-5P	100.00	76.31	3233
HSA-MIR-30B-5P	100.00	76.29	3248
HSA-MIR-30C-5P	100.00	76.29	3248
HSA-MIR-30D-5P	100.00	76.32	3233
HSA-MIR-30E-5P	100.00	76.32	3242
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-499A-5P	99.98	70.79	1323
HSA-MIR-3658	99.96	73.87	4379
HSA-MIR-497-5P	99.92	71.83	2674
HSA-MIR-3119	99.92	71.34	2390
HSA-MIR-5680	99.91	69.83	3421
HSA-MIR-15A-5P	99.90	72.80	2787
HSA-MIR-15B-5P	99.90	72.78	2798
HSA-MIR-16-5P	99.90	72.80	2780
HSA-MIR-195-5P	99.90	72.81	2805
HSA-MIR-6838-5P	99.89	71.94	2690
HSA-MIR-424-5P	99.89	71.90	2641
HSA-MIR-153-5P	99.89	73.86	6317
HSA-MIR-579-3P	99.86	71.66	3628
HSA-MIR-664B-3P	99.84	71.65	3590
HSA-MIR-3180-5P	99.82	69.12	2422
HSA-MIR-4760-5P	99.80	69.88	1619
HSA-MIR-4645-3P	99.76	69.33	993
HSA-MIR-3617-5P	99.75	69.41	1968
HSA-MIR-641	99.75	69.35	1975
HSA-MIR-4446-5P	99.72	69.19	2544
HSA-MIR-5580-3P	99.70	69.41	2052
HSA-MIR-4729	99.69	72.18	4233
HSA-MIR-646	99.68	67.84	1645
HSA-MIR-561-3P	99.64	70.90	3647

Literature-anchored findings (GeneRIF, showing 3)

• novel mutations and novel polymorphisms in coding regions and 5’UTR were detected in patients with with non-syndromic mental retardation (PMID:16425041)
• Data show that oligodendrocyte-myelin glycoprotein is downregulated in schizophrenia anterior temporal lobe revealed by shotgun proteome analysis. (PMID:19034380)
• The results do not support a relationship between the OMGP gene and the learning disability phenotype observed in neurofibromatosis type 1. (PMID:21534343)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	omga	ENSDARG00000086573
danio_rerio	omgb	ENSDARG00000089444
mus_musculus	Omg	ENSMUSG00000049612
rattus_norvegicus	Omg	ENSRNOG00000082212

Paralogs (10): EPYC (ENSG00000083782), OGN (ENSG00000106809), ECM2 (ENSG00000106823), FMOD (ENSG00000122176), OMD (ENSG00000127083), LUM (ENSG00000139329), KERA (ENSG00000139330), PRELP (ENSG00000188783), LINGO4 (ENSG00000213171), LINGO3 (ENSG00000220008)

Protein

Protein identifiers

Oligodendrocyte-myelin glycoprotein — P23515 (reviewed: P23515)

All UniProt accessions (1): P23515

UniProt curated annotations — full annotation on UniProt →

Function. Cell adhesion molecule contributing to the interactive process required for myelination in the central nervous system.

Subunit / interactions. Binds to RTN4R.

Subcellular location. Cell membrane.

Tissue specificity. Oligodendrocytes and myelin of the central nervous system.

Post-translational modifications. O-glycosylated in its Ser/Thr-rich repeat domain.

RefSeq proteins (1): NP_002535* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000372	LRRNT	Domain
IPR001611	Leu-rich_rpt	Repeat
IPR003591	Leu-rich_rpt_typical-subtyp	Repeat
IPR032675	LRR_dom_sf	Homologous_superfamily
IPR051071	LRR-bact_E3_ubiq_ligases	Family

Pfam: PF00560, PF01462, PF13855

UniProt features (31 total): repeat 13, glycosylation site 11, sequence variant 2, signal peptide 1, chain 1, lipid moiety-binding region 1, propeptide 1, domain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P23515-F1	67.94	0.47

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 417

Glycosylation sites (11): 45, 61, 103, 152, 176, 189, 192, 234, 364, 389, 425

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-193634	Axonal growth inhibition (RHOA activation)

MSigDB gene sets: 169 (showing top): AP1_01, TGCTGCT_MIR15A_MIR16_MIR15B_MIR195_MIR424_MIR497, STARK_PREFRONTAL_CORTEX_22Q11_DELETION_DN, GOBP_REGENERATION, GOBP_NEUROGENESIS, AAAYRNCTG_UNKNOWN, CAGCTG_AP4_Q5, chr17q11, MODULE_66, AP1_Q4_01, MYOD_01, SENGUPTA_NASOPHARYNGEAL_CARCINOMA_DN, TGCTGAY_UNKNOWN, WTGAAAT_UNKNOWN, OCT1_06

GO Biological Process (2): cell adhesion (GO:0007155), neuron projection regeneration (GO:0031102)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (3): plasma membrane (GO:0005886), side of membrane (GO:0098552), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
p75NTR regulates axonogenesis	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
membrane	2
cellular anatomical structure	2
cellular process	1
regeneration	1
neuron projection development	1
cellular response to stress	1
binding	1
cell periphery	1
leaflet of membrane bilayer	1

Protein interactions and networks

STRING

1478 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
OMG	RTN4R	Q9BZR6	990
OMG	MAG	P20916	983
OMG	RTN4	Q9NQC3	981
OMG	TNFRSF19	Q9NS68	942
OMG	NGFR	P08138	883
OMG	EVI2A	P22794	869
OMG	EVI2B	P34910	857
OMG	LINGO1	Q96FE5	750
OMG	RHOA	P06749	704
OMG	NF1	P21359	696
OMG	PTPRS	Q13332	694
OMG	RTN4RL1	Q86UN2	692
OMG	LILRB2	Q8N423	669
OMG	MBP	P02686	631
OMG	BDNF	P23560	629

IntAct

4 interactions, top by confidence:

A	B	Type	Score
OMG		psi-mi:“MI:0915”(physical association)	0.370
NEK4	E2F8	psi-mi:“MI:0914”(association)	0.350
MAPT	LANCL1	psi-mi:“MI:0914”(association)	0.350

BioGRID (11): OMG (Affinity Capture-MS), OMG (Affinity Capture-MS), OMG (Affinity Capture-MS), OMG (Reconstituted Complex), OMG (Affinity Capture-MS), PTPRU (Reconstituted Complex), PTPRD (Reconstituted Complex), PTPRF (Reconstituted Complex), PTPRS (Reconstituted Complex), OMG (Affinity Capture-MS), OMG (Affinity Capture-MS)

ESM2 similar proteins: A0A1Z2R986, A5D7U1, A6NHS7, F5H9T4, O02671, P11322, P15137, P15139, P16721, P16743, P20826, P21581, P21583, P22596, P23515, P35767, P35768, P35769, P35770, P40200, P48357, P79169, P79368, Q06220, Q28132, Q29030, Q3U0X8, Q5BK49, Q5HZW7, Q5W9T8, Q5XI99, Q62959, Q63912, Q66608, Q6SWB9, Q6SWC3, Q6SWC9, Q6UC88, Q6UQ28, Q7TST5

Diamond homologs: A2ARI4, A3KNN3, A4IFA6, A6H789, A6H793, A6NJW4, A8WHP9, D4AC13, E5DHB5, E7FE13, F1MLX5, F1MT22, F7D3V9, G5EFX6, O00206, O02833, O14498, O35367, O35930, O46378, O46379, O46542, O62702, O75093, O75473, O88279, O88280, O94769, O94898, P07359, P07585, P0DKB5, P0DM44, P21793, P23515, P24014, P28675, P51885, P51886, P51890

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
OMG	up-regulates	LINGO1	binding

Disease & clinical

Clinical variants and AI predictions

ClinVar

4 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	1
Likely benign	2
Benign	0

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
2422716	NC_000017.10:g.(?29422328)(29677356_?)del	Pathogenic

SpliceAI

499 predictions. Top by Δscore:

Variant	Effect	Δscore
17:31297154:A:AC	donor_gain	1.0000
17:31297155:C:CC	donor_gain	1.0000
17:31286857:A:AG	acceptor_gain	0.9900
17:31286857:AAT:A	acceptor_gain	0.9900
17:31297150:TCTTA:T	donor_loss	0.9900
17:31297151:CTTAC:C	donor_loss	0.9900
17:31297152:TTAC:T	donor_loss	0.9900
17:31297153:TA:T	donor_loss	0.9900
17:31297154:A:AG	donor_loss	0.9900
17:31297155:C:CG	donor_loss	0.9900
17:31286893:G:GC	acceptor_gain	0.9800
17:31286859:T:TA	acceptor_gain	0.9700
17:31296338:C:CC	acceptor_gain	0.9600
17:31297154:AC:A	donor_gain	0.9600
17:31297155:CC:C	donor_gain	0.9600
17:31296335:AGCC:A	acceptor_loss	0.9400
17:31296337:CCTA:C	acceptor_loss	0.9400
17:31296338:CTAG:C	acceptor_loss	0.9400
17:31296339:T:G	acceptor_loss	0.9400
17:31297149:ATCTT:A	donor_loss	0.9400
17:31297155:CCGTG:C	donor_gain	0.9400
17:31286857:AATG:A	acceptor_gain	0.9300
17:31286859:T:G	acceptor_gain	0.9300
17:31296346:A:T	acceptor_loss	0.9200
17:31296349:C:CT	acceptor_loss	0.9200
17:31296350:A:T	acceptor_loss	0.9200
17:31277332:T:G	acceptor_gain	0.9100
17:31296352:A:C	acceptor_loss	0.9100
17:31277320:T:A	acceptor_gain	0.9000
17:31296245:T:TC	acceptor_gain	0.9000

AlphaMissense

2907 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
17:31295651:C:A	W227C	0.999
17:31295651:C:G	W227C	0.999
17:31295653:A:G	W227R	0.999
17:31295653:A:T	W227R	0.999
17:31295724:A:G	F203S	0.999
17:31295729:A:C	N201K	0.999
17:31295729:A:T	N201K	0.999
17:31295731:T:A	N201Y	0.999
17:31295801:A:C	N177K	0.999
17:31295801:A:T	N177K	0.999
17:31295811:A:G	L174P	0.999
17:31295874:A:G	L153P	0.999
17:31295949:A:G	L128P	0.999
17:31296005:G:C	N109K	0.999
17:31296005:G:T	N109K	0.999
17:31296137:G:C	N65K	0.999
17:31296137:G:T	N65K	0.999
17:31296147:A:G	L62P	0.999
17:31296153:A:G	L60S	0.999
17:31296209:A:C	C41W	0.999
17:31296210:C:G	C41S	0.999
17:31296211:A:G	C41R	0.999
17:31296211:A:T	C41S	0.999
17:31295609:C:A	W241C	0.998
17:31295609:C:G	W241C	0.998
17:31295657:G:C	N225K	0.998
17:31295657:G:T	N225K	0.998
17:31295659:T:A	N225Y	0.998
17:31295730:T:A	N201I	0.998
17:31295739:A:G	L198P	0.998

dbSNP variants (sampled 300 via entrez): RS1000286742 (17:31296575 C>G), RS1000343494 (17:31296209 A>G), RS1000746571 (17:31297371 G>C), RS1001963161 (17:31294375 T>C), RS1002021814 (17:31295542 G>A), RS1003247659 (17:31298616 A>G), RS1004358292 (17:31294281 T>A,C), RS1005149167 (17:31298544 A>G,T), RS1006265289 (17:31298880 T>C), RS1006465219 (17:31298646 G>T), RS1006823712 (17:31296989 A>G,T), RS1006937888 (17:31295446 T>C,G), RS1007157397 (17:31294968 C>G), RS1008489189 (17:31294917 A>G), RS1010271652 (17:31297020 A>G)

Disease associations

OMIM: gene MIM:164345 | disease phenotypes: MIM:162200

GenCC curated gene-disease

Mondo (1): neurofibromatosis type 1 (MONDO:0018975)

Orphanet (1): Neurofibromatosis type 1 (Orphanet:636)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

4 associations (top):

Study	Trait	p-value
GCST006479_83	Diverticular disease	3.000000e-06
GCST010135_18	Oily fish consumption	3.000000e-10
GCST010140_10	Pork consumption	3.000000e-10
GCST010703_342	Brain morphology (MOSTest)	4.000000e-10

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0009959	diverticular disease
EFO:0008111	diet measurement
EFO:0004346	neuroimaging measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D009456	Neurofibromatosis 1	C04.557.580.600.580.590.650; C04.700.631.650; C10.562.600.500; C10.574.500.549.400; C10.668.829.675; C16.320.400.560.400; C16.320.700.633.650

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

13 total (human), top 13 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Tretinoin	affects expression, increases expression	2
triphenyl phosphate	affects expression	1
bisphenol A	increases expression	1
sodium bichromate	increases expression	1
CGP 52608	affects binding, increases reaction	1
2-palmitoylglycerol	increases expression	1
theaflavin-3,3’-digallate	affects expression	1
Calcitriol	increases expression	1
Malathion	affects expression	1
Quercetin	increases expression	1
Dronabinol	increases expression	1
8-Bromo Cyclic Adenosine Monophosphate	increases expression	1
Cyclosporine	increases methylation	1

Clinical trials (associated diseases)

181 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00169611	PHASE4	COMPLETED	NF1-Attention: Study of Children With Neurofibromatosis Type 1 Treated by Methylphenidate
NCT03975829	PHASE4	RECRUITING	Pediatric Long-Term Follow-up and Rollover Study
NCT02471339	PHASE3	COMPLETED	Acceptance and Commitment Training for Adolescents and Young Adults With Neurofibromatosis Type 1, Plexiform Neurofibromas, and Chronic Pain
NCT03871257	PHASE3	ACTIVE_NOT_RECRUITING	A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma
NCT04461886	PHASE3	TERMINATED	A Long-term Study of NPC-12G Gel in Neurofibromatosis Type I
NCT04924608	PHASE3	ACTIVE_NOT_RECRUITING	Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas
NCT05913037	PHASE3	ACTIVE_NOT_RECRUITING	FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas
NCT00021541	PHASE2	COMPLETED	R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas
NCT00030264	PHASE2	COMPLETED	Combination Chemotherapy in Treating Patients With Neurofibromatosis and Progressive Plexiform Neurofibromas
NCT00076102	PHASE2	COMPLETED	Pirfenidone in Children and Young Adults With Neurofibromatosis Type I and Progressive Plexiform Neurofibromas
NCT00304083	PHASE2	COMPLETED	Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors
NCT00326872	PHASE2	TERMINATED	AZD2171 in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibroma and/or Neurofibroma Near the Spine
NCT00589784	PHASE2	COMPLETED	Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma
NCT00634270	PHASE2	COMPLETED	A Phase II Study of the mTOR Inhibitor Sirolimus in Neurofibromatosis Type 1 Related Plexiform Neurofibromas
NCT00754780	PHASE2	COMPLETED	Clinical Trial of Pirfenidone in Adult Patients With Neurofibromatosis 1
NCT00846430	PHASE2	COMPLETED	Medical Treatment of High-Risk Neurofibromas
NCT00853580	PHASE2	COMPLETED	A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1
NCT01125046	PHASE2	COMPLETED	Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas
NCT01402817	PHASE2	TERMINATED	Study of Sutent®/Sunitinib (SU11248) in Subjects With NF-1 Plexiform Neurofibromas
NCT01412892	PHASE2	COMPLETED	Use of RAD001 as Monotherapy in the Treatment of Neurofibromatosis 1 Related Internal Plexiform Neurofibromas
NCT01553149	PHASE2	COMPLETED	Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma
NCT01673009	PHASE2	COMPLETED	Phase II Study of Gleevec/Imatinib Mesylate (STI-571, NCS 716051) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas
NCT01968590	PHASE2	TERMINATED	Vitamin D Supplementation for Adults With Neurofibromatosis Type 1 (NF1)
NCT02096471	PHASE2	COMPLETED	MEK Inhibitor PD-0325901 Trial in Adolescents and Adults With NF1
NCT02101736	PHASE2	COMPLETED	Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 in Children and Adults
NCT02332902	PHASE2	COMPLETED	Everolimus for Treatment of Disfiguring Cutaneous Lesions in Neurofibromatosis1 CRAD001CUS232T
NCT02407405	PHASE2	ACTIVE_NOT_RECRUITING	MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas
NCT02728388	PHASE2	RECRUITING	Photodynamic Therapy for Benign Dermal Neurofibromas- Phase II
NCT02839720	PHASE2	COMPLETED	Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Cutaneous Neurofibroma
NCT02964884	PHASE2	ACTIVE_NOT_RECRUITING	Interventions for Reading Disabilities in NF1
NCT03090971	PHASE2	COMPLETED	Use of Topical Liquid Diclofenac Following Laser Microporation of Cutaneous Neurofibromas in Patients With NF1
NCT03109301	PHASE2	WITHDRAWN	Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in People With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST)
NCT03190915	PHASE2	ACTIVE_NOT_RECRUITING	Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia
NCT03231306	PHASE2	COMPLETED	Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform Neurofibromas
NCT03433183	PHASE2	COMPLETED	SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors
NCT03741101	PHASE2	UNKNOWN	Treatment of NF1-related Plexiform Neurofibroma With Trametinib
NCT03962543	PHASE2	ACTIVE_NOT_RECRUITING	MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas
NCT04435665	PHASE2	COMPLETED	NFX-179 Topical Gel Treatment in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF)
NCT04481035	PHASE2	COMPLETED	Antioxidant Therapy With N-acetylcysteine for Learning and Motor Behavior in Children With Neurofibromatosis Type 1
NCT04481048	PHASE2	ACTIVE_NOT_RECRUITING	Antioxidant Therapy With N-acetylcysteine for Children With Neurofibromatosis Type 1